FUZ and lung adenocarcinoma: However, in the remaining 6 types, i.e. breast cancer (BRCA), esophageal adenocarcinoma (ESCA), head-neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP) and lung adenocarcinoma (LUAD), a reduced expression of Fuz was expected to contribute to decreased survival probabilities (Figure 1).